Live-attenuated simian immunodeficiency virus (SIV) protects macaques against challenge with pathogenic SIV. To evaluate the safety of such vaccines, an investigation of whether or not nefdeleted SIV could be reactivated in vivo by immune activation of the host was conducted. In addition, monkeys infected with apathogenic SIV/HIV-1 chimeric viruses, and two control monkeys that had suppressed replication of pathogenic SIV were examined. During the infection virus became undetectable or persisted at a low level of replication in all monkeys. At this time-point 11 monkeys were immune-activated by a vaccinia virus (VV) superinfection. After VV infection up to 80 % of their lymphocytes showed expression of the activation markers CD25 and CD69 over 2 weeks. However, only the two non-progressing monkeys infected with pathogenic SIV showed a noticeable but transient enhancement of SIV replication and increased SIV antibody titres. By contrast, in monkeys infected with apathogenic immunodeficiency viruses no change in virus load was observed. Therefore, attenuated immunodeficiency viruses cannot be reactivated in vivo by a VV-induced immune activation.
Live-attenuated simian immunodeficiency virus (SIV) protects macaques against challenge with pathogenic SIV. To evaluate the safety of such vaccines, an investigation of whether or not nefdeleted SIV could be reactivated in vivo by immune activation of the host was conducted. In addition, monkeys infected with apathogenic SIV/HIV-1 chimeric viruses, and two control monkeys that had suppressed replication of pathogenic SIV were examined. During the infection virus became undetectable or persisted at a low level of replication in all monkeys. At this time-point 11 monkeys were immune-activated by a vaccinia virus (VV) superinfection. After VV infection up to 80 % of their lymphocytes showed expression of the activation markers CD25 and CD69 over 2 weeks. However, only the two non-progressing monkeys infected with pathogenic SIV showed a noticeable but transient enhancement of SIV replication and increased SIV antibody titres. By contrast, in monkeys infected with apathogenic immunodeficiency viruses no change in virus load was observed. Therefore, attenuated immunodeficiency viruses cannot be reactivated in vivo by a VV-induced immune activation.
In recent years several vaccination strategies against human immunodeficiency virus (HIV) have been evaluated in the simian immunodeficiency virus (SIV) model for AIDS. By far the most successful vaccines are those based on live-attenuated SIV. These attenuated viruses have a reduced pathogenicity caused primarily by their low replicative capacity in the host. Deletions in the nef gene of SIV (SIV∆nef) have been shown to attenuate replication capacity in vivo (Kestler et al., 1991 ; Rud et al., 1994) . Moreover, an infection of rhesus macaques (Macaca mulatta) with SIV∆nef protects the monkeys against challenge with pathogenic SIV (Daniel et al., 1992 ; Almond et al., 1995 ; Norley et al., 1996 ; Stahl-Hennig et al., 1996) . Chimeric SIV that expresses the HIV-1 env gene (SHIV) was also found to be apathogenic in macaques (Li et al., 1995 ; Igarashi et al., 1994) . Such viruses have been used in vaccine studies. Despite the efficiency of live-attenuated SIV vaccines in monkeys there are safety concerns about the use of similar HIV vaccines in humans. Therefore, safety aspects have to be evaluated in detail by using relevant animal models before using replication competent retroviruses as vaccines in humans.
Since many HIV isolates are highly efficient in infecting activated CD4 lymphocytes (Kornfeld et al., 1988) , immune activation in an immunodeficiency virus-infected individual may increase their virus load. This was shown for HIVseropositive individuals immunized with different common vaccines (O'Brien et al., 1995 ; Staprans et al., 1995 ; Stanley et al., 1996 ; Ro$ sok et al., 1996) or super-infected with immunestimulating bacteria (Goletti et al., 1996) . In these reports, enhancement of virus replication seems to contribute to AIDS pathogenesis. Therefore, Corey (1995) suggested that a reduction of T-cell activation could be used as a therapy for HIV infection. In this context, we have investigated whether low-replicating or latent SIV, or SHIV, can be reactivated to give high-replicating virus by immune activation of the host. For lymphocyte stimulation in vivo, infection with a vaccinia virus (VV), described as a highly potent immunogen in several species (Demkowicz et al., 1992) including macaques (Scha$ ffner et al., 1994) , was used.
As part of an AIDS vaccine study we infected rhesus macaques with different attenuated immunodeficiency viruses. Three monkeys were infected with a molecular clone of SIV∆nef (Table 1 , group C). This virus induces low-level viraemia without full disease in macaques (Rud et al., 1994) . Similar effects on virus replication and pathogenicity have been found in monkeys infected with SHIV. In our experiment, Kuwata et al. (1995) ; b, Kuwata et al. (1996) ; c, Rud et al. (1994) ; d, Cranage et al. (1990) ; e, Regier & Desrosiers (1990) . † Duration of immunodeficiency virus infection prior to VV super-infection. p.i., Post-infection.
the SHIV constructs contained the env gene of HIV-1. These viruses are apathogenic in macaques (Igarashi et al., 1994) . Eight monkeys were infected with different SHIV constructs (Table 1 , groups A and B). In addition, two monkeys, serving as controls, were infected previously with pathogenic SIV and had repelled the virus from the peripheral blood (Table 1 , group D). Virus clearance of pathogenic SIV that allows nonprogression to AIDS occurs rarely (C. Stahl-Hennig, unpublished).
To analyse whether attenuated immunodeficiency viruses can be reactivated by an immune stimulation of the host, nine monkeys pre-infected with SIV∆nef or SHIV were superinfected with 5i10( p.f.u. of the VV strain Copenhagen . Infection was carried out at 50 (group A) or 100-120 weeks (group C) after pre-infection by scarification as described by Scha$ ffner et al. (1994) . In addition, the two wildtype SIV-infected monkeys (group D) and two naive control monkeys (group E) were included for VV infection. VV infection was monitored for clinical and seroconversion effects (Scha$ ffner et al., 1994) . Two monkeys infected solely with SHIV served as unstimulated controls (group B).
The degree of immune activation in the monkeys following VV infection was determined. Peripheral blood mononuclear cells (PBMCs) were isolated as described previously (Dittmer et al., 1995) . The expression of the activation markers CD25 (CD2R ; B1.49.9, Coulter-Immunotech) and CD69 (TP1.55.3, Coulter-Immunotech) in PBMCs was measured by flow cytometry repeatedly. In addition, lymphocyte subpopulations that were positive for CD2 (S5.2, Becton-Dickinson), CD4 (OKT4, Orthomune) and CD8 (3B5, Medac) were determined. During the course of VV infection SIV-specific antibody titres were measured on a whole virus ELISA (Stahl-Hennig et al., 1996) . HIV-1-specific anti-envelope antibody titres of SHIVinfected monkeys were measured in the same manner except that recombinant HIV-1 gp120 was used as the antigen (Programme EVA). Prior to immune activation the immunodeficiency virus-infected monkeys were monitored for virus replication, which was determined in the peripheral blood samples by a limited dilution coculture assay (Stahl-Hennig et al., 1996 ;  Fig. 1 ).
In the three SIV∆nef-infected monkeys (group C) the initial cell-associated virus load ranged between 64 and 512 infectious cells per 10' PBMCs. However, during the course of infection the virus load rapidly declined and virus could not be isolated, or only intermittently, after 16 weeks (Fig. 1 c) . At 20-40 weeks after infection these monkeys were challenged with wild-type SIV but did not allow replication of the virus. Similarly to group C, an initial virus load and subsequent decline was observed in the SHIV-infected monkeys 1866, 1870 and 1872. In contrast, virus replication in the monkeys 1841, 1853 and 1875 persisted for a longer time (Fig. 1 a) but these monkeys did not develop any signs of immunodeficiency. Monkeys 1845 and 1846 only had transient low levels of virus and no initial peak level was found ( Fig. 1 a and b) . The two control monkeys of group D, infected with the pathogenic SIV, harboured more than 1000 infectious cells per 10' PBMCs early after infection but they were found to be negative for the virus by 20 (7069) or 54 (1747) weeks after infection (Fig. 1 d) . Both monkeys remained negative for the virus and healthy until VV super-infection. At the time of VV infection, low numbers of infectious PBMCs could only be re-isolated from four of the 11 super-infected monkeys (1841, 1846, 1853 and 1872) . After VV super-infection all monkeys developed pocks around the scarification zone and VV-specific antibodies. The VV antibody titres ranged between 9 and 19 000. A similar wide variation between antibody titres to VV in macaques has also been described by Scha$ ffner et al. (1994) . The uninfected control monkeys (group B) showed no evidence of non-specific recognition of the VV antigen. The VV infection of macaques activated their PBMCs. These cells became morphologically larger and more granulated than unstimulated macaque PBMCs (data not shown), and they became positive for the activation markers CD25 and CD69 (Table 2) . About 5-15 % PBMCs from VV-uninfected monkeys were found to be positive for CD69 and only 1 % for CD25. In contrast, after VV infection up to 80 % of the macaque PBMCs showed an activated phenotype ( Table 2 ). Most of these cells ( 90 %) were CD2 + lymphocytes (data not shown). The peak of the immune response activation was found to occur 1 week after VV infection in most of the monkeys. Thereafter the number of activated cells declined again. The two VV-uninfected controls (group B) did not show any significant change in the percentage of activated lymphocyte population (Table 2) . Interestingly, both naive control monkeys (group E) exhibited a lower activation of lymphocytes after VV infection than that of the immunodeficiency virus-infected macaques.
After immune stimulation of the macaques by VV infection, only the two control monkeys of group D that were infected with pathogenic SIV showed a reactivation of SIV. In the 1841  8n8  70n8  10n9  9n4  8n3  58n4  27n7  29n0  1853  9n2  79n3  9n5  8n5  7n5  65n5  16n4  5n4  1845  8n8  65n3  11n0  10n7  7n5  58n4  20n9  14n7  1866  10n3  63n8  17n9  11n0  4n6  58n7  21n8  15n6  1870  9n1  78n0  11n4  13n2  8n1  65n9  19n0  10n0  1872  8n9  77n8  16n0  13n4  5n6  63n6  19n1  7n1  Group B  1846  8n9  11n4  14n6  9n6  11n8  15n4  19n0  16n9  1875  9n1  13n3  21n3  12n8  11n9  15n1  15n5  20n6  Group C  1821  8n9  47n5  3n3  12n7  22n7  54n3  25n2  13n4  1825  9n5  39n3  46n2  10n6  13n9  41n0  29n3  15n3  1828  9n7  49n3  85n6  10n2  17n1  48n4  39n4  10n2  Group D  1747  9n1  44n7  39n6  10n5  18n9  46n5  36n3  15n2  7069  11n2  79n3  24n8  10n5  15n4  75n5  39n2  37n4  Group E  7748  10n3  29n3  12n2  9n7  4n2  28n6  15n8  17n5  7752  9n3  34n2  8n5  9n0  7n5  32n5  31n9  32n7 * Percentage of all PBMCs expressing CD25 or CD69. p.i., Post-infection with VV.
peripheral blood of these monkeys high cell-associated virus loads were detectable 2 weeks after VV infection but dropped dramatically thereafter (Fig. 1 d) . The enhanced virus replication coincided with an increase of two log # steps of SIV-specific antibody titres appearing 2 weeks after the viraemia level had peaked. The antibody titres dropped thereafter reaching a similar level to those measured before immune activation by 20 weeks post-VV infection (data not shown). However, during the time of virus reactivation no significant change in CD4\CD8 cell ratios was observed (data not shown). Six weeks after VV infection, the two monkeys reverted to being negative for the virus and the SIV-specific antibody titres started to decrease. In contrast, the VV infection did not reactivate attenuated SIV∆nef or SHIV. Some of the monkeys showed a low level of virus replication after super-infection, whereas others remained virus free. However, none of the eight immune-activated macaques showed a remarkable increase in virus replication or reactivation of latent virus (Fig.  1 a, c) . In addition, no significant rise of SIV or HIV-1-specific antibody titres was observed (data not shown). No changes in the virological status or antibody response of the two unstimulated control monkeys of group B were detected (Fig. 1 b) .
In a previous study we showed that live-attenuated SIV rapidly protects macaques against challenge with pathogenic SIV (Stahl-Hennig et al., 1996) . Data strongly supporting the potential of these HIV vaccines have also been obtained by other groups using attenuated viruses in the SIV-macaque model (Daniel et al., 1992 ; Almond et al., 1995 ; Norley et al., 1996) . In this context the potential use of attenuated immunodeficiency viruses for immunization of humans against HIV infection can be considered to be controversial. However, a potential hazard is that replication of attenuated immunodeficiency viruses could be enhanced by immune stimulation of the host. In this study we show that attenuated SIV∆nef and SHIV have a low replication ability after an initial peak level of viraemia in macaques. Lymphocyte stimulation by VV superinfection did not increase the virus load in monkeys infected with attenuated immunodeficiency viruses. In contrast, as shown for HIV-1 in immune-activated humans (O'Brien et al., 1995 ; Staprans et al., 1995 ; Stanley et al., 1996 ; Ro$ sok et al., 1996) , in two macaques pathogenic SIV could temporarily be reactivated in vivo. Similar findings have been made by immune activation of macaques infected with pathogenic SIV during the primary phase of infection (Villinger et al., 1996) . This treatment seems to predispose the monkeys to an accelerated disease course. In contrast, our two SIV-infected monkeys were able to suppress replication of the pathogenic SIV even CFCG after its reactivation due to lymphocyte stimulation. However, it has to be taken into account that suppression of pathogenic SIV is a very rare event, and therefore only two monkeys could be investigated. Our results suggest that attenuated immunodeficiency viruses could be used in clinical trials. However, it has been shown that attenuated SIV induced an immunodeficiency in newborn rhesus macaques (Baba et al., 1995) . Furthermore, attenuated immunodeficiency viruses with small deletions in the nef gene can revert to virulence in vivo leading subsequently to immunological alterations in the host (Whatmore et al., 1995 ; Dittmer et al., 1995) . Although attenuated immunodeficiency viruses were not reactivated in vivo by our immune stimulation protocol, it seems unlikely that live-attenuated HIV-1 will be used in the near future as a human vaccine.
